Search
for
Sort by
Research 30 of 74
- Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
- Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies
- Oestrogen receptor antagonist and hair regrowth in dogs with hair cycle arrest (alopecia X)
- Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq”
- Incidence of alopecia from endocrine therapies in cancer
- Onychomatricoma with classic features: Case report and review of the literature
- An estrogen receptor pathwayregulates thetelogen-anagen hair follicle transition andinfluences epidermal cell proliferation (epidermis/estrogen/keratinocyte/differentiation/mesenchymal
- Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
- Hormone Blocking Anticancer Drugs
- Minimal systemic exposure of a new topical triazole antifungal, efinaconazole 10% solution, in patients with severe onychomycosis following 28-day treatment
- Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators
- Female Pattern Hair Loss
- Sulfatase inhibitors: a patent review
- Interventions for female pattern hair loss
- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
- Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract
- Transcriptomics analysis reveals molecular alterations underpinning spaceflight dermatology
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Novel drugs of United States Food and Drug Administration approved in 2024
- Management Of Female Pattern Hair Loss (FPHL) Using Autologous Mesenchymal Stem Cells : Report Of Two Cases
- Kalya Research: Complementary and Alternative Medicine (CAM) Virtual Research Assistant from Biomedical Literature
- Steroid Hormones of Reproduction and Sexual Development
- Index
- Cycle pilaire et alopécie X chez le chien
- Androgenetic alopecia in adolescents.
- Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
- Alopecia With Endocrine Therapies in Patients With Cancer
- Combinatorial Therapy of Letrozole- and Quercetin-Loaded Spanlastics for Enhanced Cytotoxicity against MCF-7 Breast Cancer Cells
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients